Abstract
Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast cancer, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis. Therefore, novel tools for discovery of strong prognostic and predictive markers that can be used to identify patients at high risk for relapse and aid in the selection of the most appropriate therapy are needed. This review analyzes some recent achievements in the development of such tools.
Keywords: Biomarker, breast cancer, gene signature, intrinsically disordered protein, molecular profiling, personalized medicine, prognostic factor, protein-protein interaction, transcriptome, prognosis
Current Drug Targets
Title: Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer
Volume: 13 Issue: 4
Author(s): Jiangang Liu, Shuyu Li, A. Keith Dunker and Vladimir N. Uversky
Affiliation:
Keywords: Biomarker, breast cancer, gene signature, intrinsically disordered protein, molecular profiling, personalized medicine, prognostic factor, protein-protein interaction, transcriptome, prognosis
Abstract: Breast cancer is the most common non-cutaneous cancer diagnosed in women in the United States and the second most common cause of cancer-related mortality. Over the past two decades, the progress in screening and adjuvant systemic therapies noticeably improved the survival rate. However, traditional methods of characterizing tumors are imprecise and create heterogeneous groupings of tumors and patients. As a result, despite the important medical advances in diagnosis and treatment of breast cancer, one-third of the patients with initial breast tumor have recurrence of the disease 10 years after the diagnosis. Therefore, novel tools for discovery of strong prognostic and predictive markers that can be used to identify patients at high risk for relapse and aid in the selection of the most appropriate therapy are needed. This review analyzes some recent achievements in the development of such tools.
Export Options
About this article
Cite this article as:
Liu Jiangang, Li Shuyu, Keith Dunker A. and N. Uversky Vladimir, Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer, Current Drug Targets 2012; 13 (4) . https://dx.doi.org/10.2174/138945012799499767
DOI https://dx.doi.org/10.2174/138945012799499767 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Natural Compounds with Proteasome Inhibitory Activity for Cancer Prevention and Treatment
Current Protein & Peptide Science Review: The JAK/STAT Protein Activation – Role in Cancer Development and Targeted Therapy
Current Signal Transduction Therapy Biodistribution of Lipid Nanoparticles: A Comparative Study of Pulmonary versus Intravenous Administration in Rats
Current Radiopharmaceuticals Quantitative Analysis of UGT2B28 mRNA Expression by Real-Time RT-PCR and Application to Human Tissue Distribution Study
Drug Metabolism Letters 1,3,4-Thiadiazolo (3,2-Α) Pyrimidine-6-Carbonitrile Scaffold as PARP1 Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Development and Tailoring of Hybrid Lipid Nanocarriers
Current Pharmaceutical Design 99mTc-(tricine)-HYNIC-Lys-FROP Peptide for Breast Tumor Targeting
Anti-Cancer Agents in Medicinal Chemistry Functionalized Silver Nanoparticles for Sensing, Molecular Imaging and Therapeutic Applications
Current Nanomedicine Trypsin-Chymotrypsin Inhibitors from Vigna mungo Seeds
Protein & Peptide Letters Volatilome Metabolomics and Databases, Recent Advances and Needs
Current Metabolomics MicroRNAs in Genetic Disease: Rethinking the Dosage
Current Gene Therapy Inhibition of Multidrug Resistance of Cancer Cells by Natural Diterpenes, Triterpenes and Carotenoids
Current Pharmaceutical Design Role of Genomics-Based Strategies in Overcoming Chemotherapeutic Resistance
Current Pharmaceutical Biotechnology A Lesion based and Sub-regional Comparison of FDG PET/CT and MDP Bone Scintigraphy in Detection of Bone Metastasis in Breast Cancer
Current Medical Imaging Relevance of the Neuropeptide Y System in the Biology of Cancer Progression
Current Topics in Medicinal Chemistry Psoriasin, A Multifunctional Player in Different Diseases
Current Protein & Peptide Science Effects of Limonoid Cedrelone on MDA-MB-231 Breast Tumor Cells in vitro
Anti-Cancer Agents in Medicinal Chemistry Drug Repurposing: An Emerging Tool for Drug Reuse, Recycling and Discovery
Current Drug Research Reviews Gene Transfer to the Central Nervous System: Current State of the Art of the Viral Vectors
Current Genomics The Inhibitory Effect of Cyclosporine A and Prednisolone on Both Cytotoxic CD8+ T Cells and CD4+CD25+ Regulatory T Cells
Current Signal Transduction Therapy